Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 33
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Kaaijk, Patricia and Luytjes, Willem 2016. Vaccination against Lyme disease: Are we ready for it?. Human Vaccines & Immunotherapeutics, Vol. 12, Issue. 3, p. 757.

    Kern, Aurelie Zhou, Chensheng W. Jia, Feng Xu, Qiaobing and Hu, Linden T. 2016. Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release. Vaccine,

    Small, Christina M. Mwangi, Waithaka and Esteve-Gassent, Maria D. 2016. Vaccine Design.

    Thompson, Kimberly M. and Duintjer Tebbens, Radboud J. 2016. Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples. Risk Analysis, Vol. 36, Issue. 7, p. 1487.

    Bill, Roslyn M. 2015. Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?. Journal of Pharmacy and Pharmacology, Vol. 67, Issue. 3, p. 319.

    Donohoe, Holly Pennington-Gray, Lori and Omodior, Oghenekaro 2015. Lyme disease: Current issues, implications, and recommendations for tourism management. Tourism Management, Vol. 46, p. 408.

    Ogden, Nick H. Lindsay, L. Robbin and Schofield, Steven W. 2015. Methods to Prevent Tick Bites and Lyme Disease. Clinics in Laboratory Medicine, Vol. 35, Issue. 4, p. 883.

    Hoffman, Keith B. Demakas, Andrea R. Dimbil, Mo Tatonetti, Nicholas P. and Erdman, Colin B. 2014. Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS). Drug Safety, Vol. 37, Issue. 11, p. 971.

    Nestorovich, Ekaterina M and Bezrukov, Sergey M 2014. Designing inhibitors of anthrax toxin. Expert Opinion on Drug Discovery, Vol. 9, Issue. 3, p. 299.

    Toussi, Deana and Massari, Paola 2014. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines, Vol. 2, Issue. 2, p. 323.

    Steere, Allen C. and Livey, Ian 2013. Vaccines.

    Gutiérrez, Ramiro L. and Decker, Catherine F. 2012. Prevention of Tick-Borne Illness. Disease-a-Month, Vol. 58, Issue. 6, p. 377.

    Poland, Gregory A. and Jacobson, Robert M. 2012. The clinician’s guide to the anti-vaccinationists’ galaxy. Human Immunology, Vol. 73, Issue. 8, p. 859.

    Tsao, Kimberly Fish, Durland and Galvani, Alison P. 2012. Predicted Outcomes of Vaccinating Wildlife to Reduce Human Risk of Lyme Disease. Vector-Borne and Zoonotic Diseases, Vol. 12, Issue. 7, p. 544.

    Plotkin, S. A. 2011. Correcting a Public Health Fiasco: The Need for a New Vaccine against Lyme Disease. Clinical Infectious Diseases, Vol. 52, Issue. Supplement 3, p. s271.

    Poland, G. A. 2011. Vaccines against Lyme Disease: What Happened and What Lessons Can We Learn?. Clinical Infectious Diseases, Vol. 52, Issue. Supplement 3, p. s253.

    Pozsgay, Vince Kubler-Kielb, Joanna Coxon, Bruce Marques, Adriana Robbins, John B. and Schneerson, Rachel 2011. Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease. Carbohydrate Research, Vol. 346, Issue. 12, p. 1551.

    Quine, C. P. Barnett, J. Dobson, A. D. M. Marcu, A. Marzano, M. Moseley, D. O'Brien, L. Randolph, S. E. Taylor, J. L. and Uzzell, D. 2011. Frameworks for risk communication and disease management: the case of Lyme disease and countryside users. Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 366, Issue. 1573, p. 2010.

    Shen, A. K. Mead, P. S. and Beard, C. B. 2011. The Lyme Disease Vaccine--A Public Health Perspective. Clinical Infectious Diseases, Vol. 52, Issue. Supplement 3, p. s247.

    Steinhagen, Folkert Kinjo, Takeshi Bode, Christian and Klinman, Dennis M. 2011. TLR-based immune adjuvants. Vaccine, Vol. 29, Issue. 17, p. 3341.


The Lyme vaccine: a cautionary tale

  • L. E. NIGROVIC (a1) and K. M. THOMPSON (a2) (a3)
  • DOI:
  • Published online: 01 August 2006

People living in endemic areas acquire Lyme disease from the bite of an infected tick. This infection, when diagnosed and treated early in its course, usually responds well to antibiotic therapy. A minority of patients develops more serious disease, particularly after a delay in diagnosis or therapy, and sometimes chronic neurological, cardiac, or rheumatological manifestations. In 1998, the FDA approved a new recombinant Lyme vaccine, LYMErix™, which reduced new infections in vaccinated adults by nearly 80%. Just 3 years later, the manufacturer voluntarily withdrew its product from the market amidst media coverage, fears of vaccine side-effects, and declining sales. This paper reviews these events in detail and focuses on the public communication of risks and benefits of the Lyme vaccine and important lessons learned.

Corresponding author
Division of Emergency Medicine, 300 Longwood Avenue, Children's Hospital Boston, Boston, MA 02115, USA. (Email:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *